Clinical content reviewed: 9 October 2026.
TXA is useful when the indication and timing are right. In adult emergency care, prioritize early treatment for significant traumatic bleeding and established postpartum hemorrhage (PPH). Do not give it automatically for every bleed. Pediatric care requires a separate protocol.
At the bedside: choose the indication first
Significant traumatic bleeding or risk of it: give 1 g IV over 10 minutes, then 1 g IV over 8 hours, as soon as possible and within 3 hours of injury. Check the prehospital record to avoid repeating a loading dose. Do not wait for viscoelastic confirmation of hyperfibrinolysis. European trauma guideline.
Established PPH after vaginal or cesarean birth: give 1 g IV over 10 minutes, as soon as possible and within 3 hours of birth. Repeat 1 g IV over 10 minutes if bleeding continues after 30 minutes or restarts within 24 hours of completing the first dose. Start alongside the obstetric response, rather than waiting for uterotonics to fail. WHO 2025 treatment guidance.
Shift hint: record the injury or birth time, not just arrival time. These are windows for starting treatment; they do not mean stopping the trauma infusion at 3 hours. Do not routinely start trauma TXA after 3 hours, and do not initiate it beyond 3 hours after birth for PPH.
Why it helps, and why bleeding may continue
Plasmin breaks down fibrin. TXA occupies lysine-binding sites on plasminogen and interferes with its interaction with fibrin, reducing clot breakdown. It protects the clot being formed; it does not supply platelets, fibrinogen or oxygen-carrying red cells. Drug pharmacology.
An infusion can be running while the patient continues to bleed. Continue resuscitation and source control. In PPH, TXA does not contract the uterus: uterotonics, examination for the cause and escalation remain necessary.
Evidence in one minute: CRASH-2 reduced mortality in bleeding trauma; its timing analysis found the greatest bleeding-death benefit early and a harm signal after 3 hours. WOMAN reduced bleeding deaths in PPH, especially within 3 hours, without a significant all-cause mortality reduction. Neither trial demonstrated reduced receipt of transfusion. PATCH-Trauma did not improve its primary 6-month favorable-function outcome. Avoid promising the same benefit for every outcome.
Head injury: use its own pathway
Isolated TBI is different from extracranial traumatic hemorrhage. CRASH-3 was not statistically conclusive overall; benefit appeared in the prespecified mild-to-moderate subgroup, not the severe subgroup. This is not an indication to treat every head injury.
NICE NG232 says to consider 2 g IV for people aged 16 years or older, GCS ≤12, without suspected active extracranial bleeding, as soon as possible within 2 hours of injury and before imaging. Follow the local administration protocol: this differs from the CRASH-3 regimen. Do not combine regimens or interpret “bolus” as unrestricted rapid injection.
Other situations: avoid carrying the trauma regimen across
GI bleeding: do not use TXA routinely. HALT-IT found no bleeding-death benefit from its high-dose 24-hour regimen and more venous thromboembolism and seizures. Prioritize resuscitation and definitive bleeding control.
Anterior epistaxis: topical TXA is an off-label option under local protocols, with mixed evidence. NoPAC found no reduction in packing after first aid and vasoconstrictor treatment. A 2022 trial adding TXA to phenylephrine/lidocaine found less packing and 24-hour rebleeding, but no difference at 1–7 days. These trials do not establish routine IV treatment. Persistent heavy or suspected posterior bleeding needs escalation.
Surgery: use the procedure-specific pathway. POISE-3 reduced a composite bleeding outcome in noncardiac surgery, but did not establish cardiovascular-safety noninferiority. NICE recommends TXA in primary elective hip/knee replacement with renal and route considerations. This does not establish a universal ED regimen for postoperative hemorrhage.
PPH prevention: treatment is not routine prophylaxis. WHO 2025 advises against population-wide prophylaxis at vaginal or cesarean birth. WOMAN-2 did not prevent clinically diagnosed PPH after vaginal birth in women with moderate/severe anemia. TRAAP2 improved a calculated-blood-loss/transfusion composite after cesarean birth without significant improvement in several secondary clinical outcomes, including transfusion.
Safety checks that change the decision
Renal impairment: TXA accumulates. Use indication-specific pharmacy guidance for dose adjustment, especially with repeated or prolonged dosing. The US label’s renal table addresses hemophilia-related dental extraction; it is not a universal trauma/PPH schedule. High exposure increases concern for seizures. Rapid IV administration can cause hypotension. FDA prescribing information.
Contraindications: the US label includes active intravascular clotting, subarachnoid hemorrhage and hypersensitivity to TXA or its ingredients. A TBI pathway does not authorize use for spontaneous subarachnoid hemorrhage. A remote thrombosis history is not the same as active clotting; assess the history and indication. WHO specifically cautions against PPH treatment with a known thromboembolic event during pregnancy. Stop TXA and assess new visual symptoms. FDA warnings; WHO guidance.
Never give TXA intrathecally or epidurally. Fatal errors have occurred when it was confused with spinal anesthetic ampoules. Separate storage, clear syringe labeling and drug/route checks matter. Distinguish topical orders from IV orders. FDA medication-error alert.
Before you move to the next patient
Confirm and document the indication, event time, prior doses, route and rate. Reassess blood loss, perfusion, transfusion needs and progress toward source control. Watch for a pressure drop or neurological change. Continuing bleeding is not a reason to stack extra doses outside the chosen protocol.
Remember: early TXA can support hemostasis in selected patients. It cannot replace blood, contract the uterus or stop an injured vessel from bleeding.
